Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Jeffrey S. Riesmeyer"'
1
Akademický článek
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes
Autor: Darren K. McGuire, David D’Alessio, Stephen J. Nicholls, Steven E. Nissen, Jeffrey S. Riesmeyer, Imre Pavo, Shanthi Sethuraman, Cory R. Heilmann, John J. Kaiser, Govinda J. Weerakkody
Publikováno v: Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-9 (2022)
Abstract Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational drug does not increase CV risk.
Externí odkaz: https://doaj.org/article/6108a38170714c0389cba17cd27b95c3
Zobrazit plný text záznamu
2
Akademický článek
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy
Autor: Venu Menon, Anirudh Kumar, Divyang R. Patel, Julie St. John, Kathy E. Wolski, Ellen McErlean, Jeffrey S. Riesmeyer, Govinda Weerakkody, Giacomo Ruotolo, Paul C. Cremer, Stephen J. Nicholls, A. Michael Lincoff, Steven E. Nissen
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 1 (2020)
Background The contemporary impact of glycemic control on patients with diabetes mellitus at high cardiovascular risk remains unclear. We evaluated the utility of hemoglobin A1c (HbA1c) as a marker of risk on the composite end point of cardiovascular
Externí odkaz: https://doaj.org/article/851ccfb81c9944149d295702a4eae73b
Zobrazit plný text záznamu
3
Akademický článek
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial
Autor: Anirudh Kumar, Divyang R. Patel, Danielle M. Brennan, Kathy E. Wolski, A. Michael Lincoff, Giacomo Ruotolo, Ellen McErlean, Govinda Weerakkody, Jeffrey S. Riesmeyer, Stephen J. Nicholls, Steven E. Nissen, Venu Menon
Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 23 (2019)
Background The failure of cholesteryl ester transfer protein inhibitor torcetrapib was associated with an off‐target increase in plasma aldosterone. We sought to evaluate the impact of evacetrapib on plasma aldosterone level and determine the assoc
Externí odkaz: https://doaj.org/article/11a1cfdcc6d2471fa5475695b4686ecc
Zobrazit plný text záznamu
7
The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE
Autor: Steven E. Nissen, Katherine E. Wolski, Giacomo Ruotolo, Jeffrey S. Riesmeyer, Venu Menon, A. Michael Lincoff, Ellen McErlean, Qiuqing Wang, Govinda Weerakkody, Stephen J. Nicholls, Nishant P. Shah, Leslie Cho
Publikováno v: Diabetes Care. 43:e22-e24
Despite optimal medical treatment, patients with diabetes and established atherosclerotic disease remain at high risk for recurrent cardiovascular events. Consequently, identification and modification of novel risk factors that mediate residual risk
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4141ad3b18107ff0a0c947c01d5b357
https://doi.org/10.2337/dc19-1117
Zobrazit plný text záznamu
8
Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
Autor: Maureen J. Lage, Luis-Emilio Garcia-Perez, Matthew C. Riddle, Kristina S. Boye, Chrisanthi A. Karanikas, Mark Lakshmanan, Jeffrey S. Riesmeyer, Reema Mody, Hertzel C. Gerstein
Publikováno v: Diabetes, Obesity & Metabolism
AIM To examine the generalizability of results from glucagon-like peptide-1 receptor agonist (GLP-1 RA) cardiovascular outcome trials (CVOTs) in the US type 2 diabetes (T2D) population. MATERIALS AND METHODS Patients enrolled or eligible for inclusio
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24e1f32524949c2a60265a3b267a0a94
http://europepmc.org/articles/PMC6593714
Zobrazit plný text záznamu
9
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial
Autor: Jeffrey S. Riesmeyer, Govinda Weerakkody, A. Michael Lincoff, Kathy Wolski, Anirudh Kumar, Divyang Patel, Sangeeta R. Kashyap, Venu Menon, Stephen J. Nicholls, Ellen McErlean, Steven E. Nissen, Giacomo Ruotolo
Publikováno v: Diabetes and Vascular Disease Research. 16:171-177
Background: Despite optimal treatment, type II diabetes mellitus remains associated with an increased risk for future cardiovascular events. We sought to determine the association between baseline fasting plasma insulin levels and major adverse cardi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8122b6aaea6c290111d53e2adbce53b
https://doi.org/10.1177/1479164119827604
Zobrazit plný text záznamu
10
Abstract 13426: The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
Autor: Giacomo Ruotolo, Deborah A. Robins, Kevin L. Duffin, Jonathan M. Wilson, Lenden M. Bowsman, Amy L. Cox, Yanzhu Lin, Jeffrey S. Riesmeyer, Gary Considine, Axel Haupt
Publikováno v: Circulation. 142
Introduction: The dual GIP/GLP-1 receptor agonist tirzepatide dose-dependently reduced HbA1c and body weight in patients with obesity and type 2 diabetes (T2D) in a Phase 2 trial. Hypothesis: In this post hoc analysis, additional biomarkers of inflam
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::775beabda4f663b145c88480db8d9ad2
https://doi.org/10.1161/circ.142.suppl_3.13426
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje